Ionis Pharmaceu…
ProfileJobs

Ionis Pharmaceuticals

Suggest Edit
    • Healthbiotechdrug developmentpaymentspharmaplatform
    We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.

    With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy. 

    Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.
    Show more
    Revenue(FY, 2017)
    $507.7 M
    Market capitalization(2017-10-31)
    $7.1 B
    Type
    Public
    HQ
    Carlsbad, US
    Founded
    1989
    Size (employees)
    435 (est)
    Website
    ionispharma.com
    Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, US
    Report incorrect company information

    Key People/Management at Ionis Pharmaceuticals

    Stanley Crooke

    Stanley Crooke

    CEO
    Lynne Parshall

    Lynne Parshall

    COO / CFO
    Elizabeth Hougen

    Elizabeth Hougen

    Chief Accounting Officer
    C. Frank Bennett

    C. Frank Bennett

    Senior Vice President of Research
    Sarah Boyce

    Sarah Boyce

    CBO
    Steve Hughes

    Steve Hughes

    Chief Clinical Development Officer
    Show more

    Ionis Pharmaceuticals Office Locations

    Ionis Pharmaceuticals has an office in Carlsbad
    Carlsbad, US (HQ)
    2855 Gazelle Ct
    Show all (1)
    Report incorrect company information

    Ionis Pharmaceuticals Financials and Metrics

    Ionis Pharmaceuticals Financials

    Ionis Pharmaceuticals's revenue was reported to be $507.67 m in FY, 2017
    USD

    Revenue (FY, 2017)

    		507.7 m

    Net income (FY, 2017)

    		(17.3 m)

    EBIT (FY, 2017)

    		24.5 m

    Market capitalization (31-Oct-2017)

    		7.1 b

    Closing share price (31-Oct-2017)

    		58.3

    Cash (31-Dec-2017)

    		129.6 m
    Ionis Pharmaceuticals's current market capitalization is $7.1 b.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		147.3 m214.2 m283.7 m346.6 m507.7 m

    Revenue growth, %

    		45%32%22%

    General and administrative expense

    		48.6 m108.5 m

    Operating expense total

    		48.6 m483.1 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Revenue

    		23.6 m28.2 m57.1 m44.1 m62.6 m120.4 m49.1 m36.9 m38.5 m110.9 m110.3 m104.2 m120.9 m

    General and administrative expense

    		3.4 m4.4 m4.5 m4.5 m7.5 m7.8 m8.8 m10.6 m9.8 m10.2 m13.7 m22.3 m

    Operating expense total

    		49.1 m57.8 m63.7 m65.6 m71.9 m75.8 m97.3 m91.5 m87.4 m94.8 m96.3 m105.8 m107 m

    EBIT

    		(25.5 m)(29.7 m)(6.7 m)(21.5 m)(9.3 m)44.6 m(48.1 m)(54.7 m)(48.9 m)16.1 m14 m(1.7 m)13.9 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		160 m143 m128.8 m84.7 m129.6 m

    Accounts Receivable

    		51.1 m

    Inventories

    		8 m6.3 m6.9 m7.5 m10 m

    Current Assets

    		735.5 m836.6 m837 m797.9 m1.2 b
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Cash

    		256.4 m161.8 m94.1 m73.2 m148.3 m119.5 m126.6 m93.3 m112.5 m84.3 m114.2 m133 m159.2 m

    Inventories

    		7.4 m7.5 m7.8 m7.1 m6.8 m6.8 m6.6 m6.5 m7.7 m9.3 m6.8 m6.5 m8.5 m

    Current Assets

    		763.3 m722.1 m705.8 m681.2 m835.4 m855.5 m868.3 m763.9 m698 m730.3 m962.4 m964.4 m1.1 b

    PP&E

    		87.3 m86.6 m86.3 m88.1 m89 m89.7 m89.2 m90.4 m90.6 m91 m95.4 m99.7 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(60.6 m)(39 m)(88.3 m)(86.6 m)(17.3 m)

    Depreciation and Amortization

    		6.6 m6.4 m7 m7.5 m6.7 m

    Inventories

    		(1.9 m)1.7 m(609 k)(590 k)(2.5 m)

    Accounts Payable

    		66 k4.8 m9.2 m(10.7 m)1.8 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    		(24.6 m)(31.3 m)(12.1 m)(26.7 m)(16.7 m)35.6 m(35.8 m)(62.9 m)(56.9 m)7.4 m3.5 m(4.9 m)

    Inventories

    		7.8 m7.1 m6.8 m6.8 m6.6 m6.5 m7.7 m9.3 m6.8 m8.5 m

    Accounts Payable

    		13.5 m15.6 m16.5 m11 m19.3 m19.5 m17.6 m15.7 m23.2 m23.5 m
    show all
    USDY, 2017

    Revenue/Employee

    		1.2 m

    Financial Leverage

    		3.2 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Repligen
    Health - Public
    Karyopharm Therapeutics
    Health - Subsidiary
    AcelRx Pharmaceuticals
    Health - Public
    Intercept Pharmaceuticals
    Health - Public
    Compare competitors
    Download PDF